5:57 PM
 | 
Jun 11, 2010
 |  BC Extra  |  Company News

Repros gains on partial lift of clinical hold

Repros Therapeutics Inc. (NASDAQ:RPRX) gained $0.08 (16%) to $0.56 on Friday after FDA replaced a full clinical hold on Proellex with a partial hold so that the company can conduct a Phase II...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >